

G-Protein Coupled Receptor Consortium (GPCR)

 consortiapedia.fastercures.org/consortia/gpcr/

Research Areas



Basic Research



Data-Sharing Enabler



Product Development

Data, Drugs

At a Glance

- Status: **Active Consortium**
- Year Launched: **2014**
- Initiating Organization: **Amgen, Sanofi, ONO**
- Initiator Type: **Nonprofit foundation**
- Location: **International**

Abstract

The GPCR Consortium is a not for profit entity formed to bring together industry and academic scientists to advance GPCR research for drug development. The goal of the GPCR Consortium is to generate high-resolution pictures of hundreds of medically important GPCRs.

Mission

The GPCR Consortium is data-centric, with the primary objective being dissemination of protein structural coordinates, reagents, and supporting data to both the consortium members and the broader scientific community. All research outputs such as three-dimensional structures of GPCRs and constructs will be compiled and placed in the public domain. The consortium members contribute chemical compounds and nominate GPCR targets prioritized in disease areas. The GPCR Consortium hopes to attract up to five additional industry members to achieve the goal of determining structures of 200 of the 826 known human GPCRs, prioritized in disease areas that initially include diabetes, cancer, and mental disorders.

Consortium History

GPCR Consortium was launched in 2014

Structure & Governance

The GPCR Consortium was started by Professor Raymond Stevens, who is focused on the structure and function of GPCRs and human cell signaling, and is coordinated by Dr. Michael Hanson, a leader in GPCR structural biology.

Financing

GPCR is funded by the National Institute of Health Protein Structure Initiative

Intellectual Property

GPCR provides pre-competitive access to structural information, materials, and related data.

Links/Social Media Feed

Homepage

<http://gpcrconsortium.org/>

Points of Contact

http://gpcrconsortium.org/?page_id=4

Sponsors & Partners

Amgen (United States)
Sanofi (Europe)
ONO (Japan)
Pfizer
H. Lundbeck A/S
Boehringer Ingelheim
Taisho Pharmaceutical Co.
Novo
Merk & Co.
Nordisk

Updated: **06/20/2017**